Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.

Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD.

J Am Soc Nephrol. 1998 Oct;9(10):1924-30.

2.

Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion.

Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS.

Gastroenterology. 1995 Mar;108(3):752-60.

PMID:
7875477
3.

Sodium polystyrene sulfonate resin candy for control of potassium in chronic dialysis patients.

Johnson K, Cazee C, Gutch C, Ogden D.

Clin Nephrol. 1976 Jun;5(6):266-8.

PMID:
1277599
4.

[Electrolyte and acid-base balance disorders in advanced chronic kidney disease].

Alcázar Arroyo R.

Nefrologia. 2008;28 Suppl 3:87-93. Spanish.

5.

Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis.

Kim DM, Chung JH, Yoon SH, Kim HL.

Nephrol Dial Transplant. 2007 Nov;22(11):3273-6. Epub 2007 Jul 5.

6.

A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.

Kaisar MO, Wiggins KJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Mudge DW, Bofinger A, Petrie JJ, Johnson DW.

Am J Kidney Dis. 2006 May;47(5):809-14.

PMID:
16632019
7.

Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.

Wenzl HH, Fine KD, Santa Ana CA, Porter JL, Fordtran JS.

Dig Dis Sci. 1997 Jan;42(1):119-28.

PMID:
9009126
8.

Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis.

Rivard AL, Raup SM, Beilman GJ.

JPEN J Parenter Enteral Nutr. 2004 Mar-Apr;28(2):76-8.

PMID:
15080600
9.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
10.

Damned if you do, damned if you don't: potassium binding resins in hyperkalemia.

Watson M, Abbott KC, Yuan CM.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1723-6. doi: 10.2215/CJN.03700410. Epub 2010 Aug 26.

12.
14.

Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease.

Singhal PC, Desroches L, Mattana J, Abramovici M, Wagner JD, Maesaka JK.

Am J Nephrol. 1993;13(2):138-41.

PMID:
8342580
15.

Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease.

Gutierrez R, Schlessinger F, Oster JR, Rietberg B, Perez GO.

Miner Electrolyte Metab. 1991;17(5):297-302.

PMID:
1668124
16.

Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

Sterns RH, Rojas M, Bernstein P, Chennupati S.

J Am Soc Nephrol. 2010 May;21(5):733-5. doi: 10.1681/ASN.2010010079. Epub 2010 Feb 18.

18.

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia.

Bennett LN, Myers TF, Lambert GH.

Am J Perinatol. 1996 Apr;13(3):167-70. Review.

PMID:
8688109
19.

Lithium absorption prevented by sodium polystyrene sulfonate in volunteers.

Tomaszewski C, Musso C, Pearson JR, Kulig K, Marx JA.

Ann Emerg Med. 1992 Nov;21(11):1308-11.

PMID:
1416323
20.

Mineral content of infant formula after treatment with sodium polystyrene sulfonate or calcium polystyrene sulfonate.

Fassinger N, Dabbagh S, Mukhopadhyay S, Lee DY.

Adv Perit Dial. 1998;14:274-7.

PMID:
10649740
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk